Position and practical use of fingolimod in Europe-Reference-Cited by-同舟云学术

Position and practical use of fingolimod in Europe

Published:2014-02 Issue:1 Volume:5 Page:19-33
ISSN:1759-1961
Container-title:Clinical and Experimental Neuroimmunology
language:en
Short-container-title:Clin Exp Neuroimmunol

Author:

Comi Giancarlo¹

Affiliation:

1. Department of Neurology; University Vita-Salute San Raffaele; San Raffaele Scientific Institute; Milan Italy

Publisher

Wiley

Subject

Clinical Neurology,Immunology and Microbiology (miscellaneous),Immunology,Neuroscience (miscellaneous)

Reference96 articles.

1. Fingolimod New Drug Approval Letter, US Food and Drug Administration http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022527s000ltr.pdf

2. Fingolimod Approval Letter, European Medicines Agency http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002202/WC500101043.pdf

3. Novartis 2013

4. Gilenya World Watch http://gilenya-world-watch.com/English.html

5. Gilenya US Prescribing Information http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022527s000lbl.pdf

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The S1P–S1PR Axis in Neurological Disorders—Insights into Current and Future Therapeutic Perspectives;Cells;2020-06-22

2. Modifying therapies for the treatment of relapse-remitting multiple sclerosis;British Journal of Healthcare Management;2017-10-02

3. Disease modifying therapies for the treatment of relapse-remitting multiple sclerosis;Nurse Prescribing;2017-05-02

4. Optimizing therapy early in multiple sclerosis: An evidence-based view;Multiple Sclerosis and Related Disorders;2015-09

5. Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study;Multiple Sclerosis International;2015